Zhen Lu

No ORCID on file · 4 papers in corpus
review 2017
The role of biomarkers in the management of epithelial ovarian cancer
Expert review of molecular diagnostics ·doi:10.1080/14737159.2017.1326820

Despite advances in surgery and chemotherapy for ovarian cancer, 70% of women still succumb to the disease. Biomarkers have contributed to the management of ovarian cancer by monitoring response to treatment, detecting recurrence, distingui…

lab-animal 2015
MiR-10b Directly Targets ZEB1 and PIK3CA to Curb Adenomyotic Epithelial Cell Invasiveness via Upregulation of E-Cadherin and Inhibition of Akt Phosphorylation
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology ·doi:10.1159/000374022

BACKGROUND/AIMS: Adenomyosis is a disease in which ectopic endometrial glands and stromal cells appear in the uterine myometrium. Despite its prevalence, the molecular mechanisms involved in the development of adenomyosis are largely unknow…

lab-animal 2009
CA125/MUC16 is dispensable for mouse development and reproduction
PloS one ·doi:10.1371/journal.pone.0004675

Cancer antigen 125 (CA125) is a blood biomarker that is routinely used to monitor the progression of human epithelial ovarian cancer (EOC) and is encoded by MUC16, a member of the mucin gene family. The biological function of CA125/MUC16 an…

other 2007
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment
Gynecologic Oncology ·doi:10.1016/j.ygyno.2007.04.022

OBJECTIVES: Early detection of ovarian cancer should improve overall survival. Multiple serum markers have been evaluated as possible tests to detect early stage disease, but few urine markers have been studied. Mesothelin has been detected…